XERIS BIOPH.HOL. DL-0001
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and… Read more
Market Cap & Net Worth: XERIS BIOPH.HOL. DL-0001 (2B30)
XERIS BIOPH.HOL. DL-0001 (F:2B30) has a market capitalization of $800.49 Million (€779.84 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #8445 globally and #911 in its home market, demonstrating a -4.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XERIS BIOPH.HOL. DL-0001's stock price €4.70 by its total outstanding shares 165924289 (165.92 Million).
XERIS BIOPH.HOL. DL-0001 Market Cap History: 2018 to 2026
XERIS BIOPH.HOL. DL-0001's market capitalization history from 2018 to 2026. Data shows change from $2.55 Billion to $800.49 Million (-15.42% CAGR).
XERIS BIOPH.HOL. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XERIS BIOPH.HOL. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2B30 by Market Capitalization
Companies near XERIS BIOPH.HOL. DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to XERIS BIOPH.HOL. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
XERIS BIOPH.HOL. DL-0001 Historical Marketcap From 2018 to 2026
Between 2018 and today, XERIS BIOPH.HOL. DL-0001's market cap moved from $2.55 Billion to $ 800.49 Million, with a yearly change of -15.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €800.49 Million | -24.07% |
| 2025 | €1.05 Billion | +91.64% |
| 2024 | €550.12 Million | +53.81% |
| 2023 | €357.67 Million | +82.58% |
| 2022 | €195.90 Million | -47.72% |
| 2021 | €374.70 Million | -48.60% |
| 2020 | €728.96 Million | -34.66% |
| 2019 | €1.12 Billion | -56.25% |
| 2018 | €2.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of XERIS BIOPH.HOL. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $800.49 Million USD |
| MoneyControl | $800.49 Million USD |
| MarketWatch | $800.49 Million USD |
| marketcap.company | $800.49 Million USD |
| Reuters | $800.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.